BIOTRONIK Launches World’s First CE-Approved LBBAP High-Voltage Devices with Acticor Sky and Rivacor Sky
Published: 13 Feb 2026
Author: Precedence Research
BIOTRONIK reported the commercial release of its new Acticor Sky and Rivacor Sky family of devices. This introduces the first high-voltage pacing implantable systems to be CE-approved that aim to support left bundle branch area pacing (LBBAP). The new generation of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) are currently available across the entire CE-mark.
It represents a significant breakthrough in the area of physiological pacing and the management of arrhythmia. As the conduction system pacing continues to gain traction with the electrophysiologists. The novel platform represents a resounding move in the direction of more natural cardiac activation strategies without compromising defibrillation capabilities.
The Acticor Sky and Rivacor Sky platforms present specific programming tools and simplified workflows to facilitate the implementation of LBBAP in daily clinical practice. Left bundle branch area pacing allows increased physiologic ventricular activation, direct contact with the intrinsic conduction system of the heart and generates more synchronized contractions than traditional right ventricular pacing. Such a solution can promote improved hemodynamic performance and, probably, decrease the incidence of pacing-induced cardiomyopathy. Furthermore, the advent of the fully approved LBBAP-capable high-voltage devices puts BIOTRONIK at the forefront of the pacing conduction system innovation.
Executives Statements
Dr. Andreas Hecker, Chief Technology Officer at BIOTRONIK, commented
With Acticor and Rivacor Sky, we created a platform that elevates cardiac care. This new device family combines proven reliability with advanced algorithms to tailor therapy more precisely while simplifying workflows that support physicians in their daily work.
Dr. Anastasia Falagkari, Senior Attending Physician for Electrophysiology at University Hospital Frankfurt, stated
The device’s streamlined programming and diagnostics were immediately noticeable. Pacing in the left bundle branch area provides more physiological and synchronized heart contractions, which is exactly what we aim for in resynchronization therapy. CRT-DX technology allows a dual-lead CRT approach, contributing to a more efficient implantation procedure. In addition, based on the two-lead-only approach, it is very likely to reduce the complication risk in the future.